SCHEMBL2887144

SCHEMBL2887144

CC(=O)/C=C/c1ccc2ccccc2c1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
CYP3A4 P08684 2/20 0.58
PTPN1 P18031 2/20 0.58
PTGS1 P23219 2/20 0.58
IAPP P10997 1/20 0.58
CYP1A2 P05177 2/20 0.55
MEN1 O00255 1/20 0.55
NPC1 O15118 1/20 0.55
CYP2C19 P33261 1/20 0.55
RAB9A P51151 1/20 0.55
KMT2A Q03164 1/20 0.55
RELA Q04206 1/20 0.55
CYP1A1 P04798 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP1B1 Q16678 1/20 0.54
APP P05067 1/20 0.54
MAPT P10636 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29637954 1.00 GLA (0.60) GLATDP1CYP3A4PTPN1PTGS1
SCHEMBL29931049 1.00 GLA (0.60) GLATDP1CYP3A4PTPN1PTGS1
SCHEMBL2887149 1.00 GLA (0.60) GLATDP1CYP3A4PTPN1PTGS1
SCHEMBL14016920 0.92 IAPP (0.66) GLATDP1CYP3A4PTPN1PTGS1
SCHEMBL2744147 0.85 CYP3A4 (0.61) CYP3A4PTPN1PTGS1CYP1A2MEN1
SCHEMBL2744149 0.85 CYP3A4 (0.61) CYP3A4PTPN1PTGS1CYP1A2MEN1
SCHEMBL9579426 0.84 PTGS1 (0.61) GLATDP1CYP3A4PTGS1IAPP
SCHEMBL78427 0.83 RELA (0.62) GLATDP1CYP3A4PTPN1PTGS1
SCHEMBL78426 0.83 RELA (0.62) GLATDP1CYP3A4PTPN1PTGS1
SCHEMBL6552210 0.83 RELA (0.62) GLATDP1CYP3A4PTPN1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3502109-A1 TRIAZOLE-PHENYL-THIAZOLE HETEROCYCLES AS INNOVATIVE INHIBITORS OF TRYPANOTHIONE REDUCTASE AND THEIR USE AS LEISHMANICIDES Consejo Superior De Investigaciones Científicas (ES) 2019-06-26 EP disclosed
US-8309715-B2 Camphor-derived β-amino alcohol compounds, method for manufacturing the same and asymmetric addition of organozinc to aldehydes using the same NATIONAL TSING HUA UNIVERSITY (TW) 2012-11-13 US disclosed
US-20110313159-A1 CAMPHOR-DERIVED BETA-AMINO ALCOHOL COMPOUNDS, METHOD FOR MANUFACTURING THE SAME AND ASYMMETRIC ADDITION OF ORGANOZINC TO ALDEHYDES USING THE SAME NATIONAL TSING HUA UNIVERSITY (TW) 2011-12-22 US disclosed
US-20100121069-A1 METHOD FOR MANUFACTURING A BETA-DIARYL ELECTRON WITHDRAWING GROUP SUBSTITUTED COMPOUND MSD K.K. (JP) 2010-05-13 US disclosed
EP-2042478-A1 METHOD FOR PRODUCING -DIARYL ELECTRON-WITHDRAWING GROUP SUBSTITUTED COMPOUND Japan Science and Technology Agency (JP) 2009-04-01 EP disclosed
US-4680400-A Herbicidal cyclohexane-1,3-dione-5-isoquinoline derivatives ICI AUSTRALIA LIMITED (AU) 1987-07-14 US disclosed
US-4640708-A Herbicidal cyclohexane-1,3-dione derivatives ICI AUSTRALIA LIMITED (AU) 1987-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110313159-A1 CAMPHOR-DERIVED BETA-AMINO ALCOHOL COMPOUNDS, METHOD FOR MANUFACTURING THE SAME AND ASYMMETRIC ADDITION OF ORGANOZINC TO ALDEHYDES USING THE SAME ADH1C, DDC, DCXR GLA 3862/4885TDP1 4369/4885CYP3A4 1480/4885
US-20100121069-A1 METHOD FOR MANUFACTURING A BETA-DIARYL ELECTRON WITHDRAWING GROUP SUBSTITUTED COMPOUND BMP6, GPR6, ACSL6 GLA 1172/4885TDP1 3153/4885CYP3A4 519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.